On Thursday, TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback